| Literature DB >> 36013009 |
Jimena Rodríguez-Carbó1, José M Torres-Arellano2, Nydia Ávila-Vanzzini3, Rashidi Springall4, Rafael Bojalil5, Oscar Infante2, Claudia Lerma2, Juan Carlos Echeverría6.
Abstract
The aim of this work was to obtain insights of the participation of the autonomic nervous system in different stages of calcific aortic valve disease (CAVD) by heart rate variability (HRV) analysis. Studying subjects with no valve impairments and CAVD patients, we also sought to quantify the independent contribution or explanatory capacity of the aortic valve echocardiographic parameters involved in the HRV changes caused by active standing using hierarchical partitioning models to consider other variables or potential confounders. We detected smaller adjustments of the cardiac autonomic response at active standing caused specifically by the aortic valve deterioration. The highest association (i.e., the highest percentage of independent exploratory capacity) was found between the aortic valve area and the active standing changes in the short-term HRV scaling exponent α1 (4.591%). The valve's maximum pressure gradient echocardiographic parameter was present in most models assessed (in six out of eight models of HRV indices that included a valve parameter as an independent variable). Overall, our study provides insights with a wider perspective to explore and consider CAVD as a neurocardiovascular pathology. This pathology involves autonomic-driven compensatory mechanisms that seem generated by the aortic valve deterioration.Entities:
Keywords: active standing; autonomic nervous system; calcific aortic valve disease; heart rate variability; hierarchical partitioning
Year: 2022 PMID: 36013009 PMCID: PMC9409634 DOI: 10.3390/jcm11164771
Source DB: PubMed Journal: J Clin Med ISSN: 2077-0383 Impact factor: 4.964
Figure 1Example of HRV time series from one NAV subject (upper panels), one AVSc patient (middle panels) and one AVSt patient (lower panels) while they were in supine position (left panels) and active standing (right panel). The NAV subject is a 46-year-old man with a BMI of 25.565 kg/m2, a Vmax of 1.2 m/s, an AVA of 3.9 cm2, an AVAi of 2.02 cm2/m2, a PGmean of 2 mmHg, a PGmax of 5 mmHg and an LVEF of 60%. The AVSc patient corresponds to a 30-year-old-man with a BMI of 26.3 kg/m2, a Vmax of 1.05 m/s, an AVA of 4.2 cm2, an AVAi of 2.2 cm2/m2, a PGmean of 2 mmHg, a PGmax of 4 mmHg and an LVEF of 68%. The AVSt patient is a 53-year-old man with a BMI of 30.191 kg/m2, a Vmax of 5.6 m/s, an AVA of 0.5 cm2, an AVAi of 0.25 cm2/m2, a PGmean of 57 mmHg, a PGmax of 97 mmHg and an LVEF of 55%. MeanNN: mean value of all NN intervals in the time series, NAV: normal aortic valve, AVSc: aortic valve sclerosis, AVSt: aortic valve stenosis. ΔmeanNN: the difference between meanNN values at the supine position minus values at active standing.
Figure 2Conceptual framework of the studied variables. Vmax: maximum aortic valve transvalvular velocity; PGmean: mean pressure gradient, PGmax: maximum pressure gradient; AVA: aortic valve area, AVAi: aortic valve area indexed to body surface area; Δ: the difference between values of heart rate variability (HRV) indices at the supine position minus values at active standing; meanNN: mean value of all NN intervals (RR intervals from sinus rhythm); SDNN: standard deviation of all NN intervals; RMSSD: root mean squared of the successive differences; pNN20: percentage of successive NN intervals with differences greater than 20 ms; LF: low-frequency band spectral power; HF: high-frequency band spectral power, n.u.: normalized units; LF/HF: ratio between low-frequency and high frequency spectral powers; α1: short-term scaling exponent, SampEn: sample entropy; MMPs: matrix metalloproteinases; TIMP1: tissue inhibitor of metalloproteinase-1.
Figure 3Schematic representation of hierarchical partitioning analysis applied to each of the 11 dependent variables (HRV indices). The pre-selected variables were distinctive for each of the 11 HRV indices. * A multiple linear stepwise regression model was applied for each category of independent variables and covariables as described in Figure 2.
Anthropometric and clinical values of participants. Data are shown as absolute value (percentage), mean ± standard deviation, or median (percentile 25, percentile 75).
| Variable | NAV | AVSc | AVSt | |
|---|---|---|---|---|
| Age (years) | 41.3 ± 7.9 | 45.3 ± 9.3 | 63.3 ± 6.6 ^° | <0.001 |
| Female | 10 (45%) | 40 (55%) | 11 (34%) | 0.150 |
| BMI (kg/m2) | 25.9 (24.9, 29.4) | 27.0 (24.9, 30.3) | 28.2 (26.7, 32.2) | 0.141 |
| DBP (mmHg) & | 78 (70, 80) | 78 (70, 81) | 80 (70, 83) | 0.478 |
| SBP (mmHg) & | 110 (108, 118) | 116 (110, 123) | 136 ± 21.4 ^° | <0.001 |
| MBF (Hz) | 0.27 ± 0.05 | 0.27 (0.22, 0.31) | 0.33 ± 0.08 ^° | 0.002 |
| Medication intake & | 6 (27%) | 18 (25%) | 24 (75%) ^° | <0.001 |
| Hypertension | 2 (9%) | 4 (5%) | 16 (50%) ^° | <0.001 |
| Smoking | 6 (27%) | 26 (36%) | 12 (38%) | 0.714 |
| Diabetes | 0 (0 %) | 2 (3%) | 7 (22%) ° | <0.001 |
^ Comparing with NAV (p < 0.017); ° Comparing with AVSc (p < 0.017). p: adjusted value of p according to the Bonferroni correction for multiple comparisons. NAV: normal aortic valve; AVSc: aortic valve sclerosis; AVSt: aortic valve stenosis; BMI: body mass index; SBP: systolic blood pressure; DBP: diastolic blood pressure; MBF: mean breathing frequency. Medication intake: being under any pharmacological treatment. & In the variables DBP and SBP, the total number of subjects was 107 (NAV = 21, AVSc = 57 and AVSt = 29); in Medication intake the total number of subjects was 125 (NAV = 22, AVSc = 71 and AVSt = 32).
Parameters evaluated from the echocardiogram that depict the valve function. Data are shown as mean ± standard deviation, or median (percentile 25, percentile 75).
| Variable | NAV | AVSc | AVSt | |
|---|---|---|---|---|
| Vmax (m/s) | 1.2 ± 0.3 | 1.3 ± 0.2 | 4.4 ± 1.2 ^° | <0.001 |
| PGmean (mmHg) | 3 (2, 3) | 3 (2, 4) | 41 (23, 71) ^° | <0.001 |
| PGmax (mmHg) | 5.3 ± 2.2 | 6 (4, 7) | 69 (37.2, 114.7) ^° | <0.001 |
| AVA (cm2) | 4.1 ± 0.2 | 4.1 (4, 4.3) | 0.6 (0.4, 1.3) ^° | <0.001 |
| AVAi (cm2/m2) | 2.2 ± 0.2 | 2.3 ± 0.3 | 0.4 (0.3, 0.7) ^° | <0.001 |
^ Comparing with NAV (p < 0.017); ° Comparing with AVSc (p < 0.017). p: adjusted value of p according to the Bonferroni correction for multiple comparisons. NAV: normal aortic valve; AVSc: aortic valve sclerosis; AVSt: aortic valve stenosis; Vmax: maximum aortic valve transvalvular velocity; PGmean: mean pressure gradient; PGmax: maximum pressure gradient; AVA: aortic valve area; AVAi: aortic valve area indexed to body surface area.
Parameters evaluated from the echocardiogram that depict the ventricular function. Data are shown as mean ± standard deviation, or median (percentile 25, percentile 75).
| Variable | NAV | AVSc | AVSt | |
|---|---|---|---|---|
| LVEF (%) | 61.9 ± 6.4 | 62.3 ± 6.6 | 55 (51, 60) ^° | <0.001 |
| LVM (g) | 98 (86, 105) | 117 (96, 155.7) | 216.9 ± 67.1 ^° | <0.001 |
| LVMi (g/m2) | 54.7 ± 12.1 | 65 (56.7, 77) ^ | 119.8 ± 34.7 ^° | <0.001 |
| RWT | 0.4 ± 0.1 | 0.4 ± 0.1 | 0.5 ± 0.2 ^° | <0.001 |
^ Comparing with NAV (p < 0.017); ° Comparing with AVSc (p < 0.017). p: adjusted value of p according to the Bonferroni correction for multiple comparisons. NAV: normal aortic valve; AVSc: aortic valve sclerosis; AVSt: aortic valve stenosis; LVEF: left ventricular ejection fraction; LVM: left ventricular mass; LVMi: left ventricular mass indexed to body surface area; RWT: relative wall thickness.
Magnitude (Δ) of change in heart rate variability indices in response to active standing. Data are shown as mean ± standard deviation, or median (percentile 25, percentile 75). The n specifies the number of subjects in each group.
| Variable | NAV ( | AVSc ( | AVSt ( | |
|---|---|---|---|---|
| ΔpNN20 (%) | 8.9 ± 7.3 | 9.9 ± 9.0 | 5.4 ± 10.2 | 0.060 |
| ΔmeanNN (s) | 0.2 ± 0.1 | 0.2 ± 0.1 | 0.1 (0.0, 0.1) ^° | 0.001 |
| ΔRMSSD (ms) | 10.9 (7.0, 16.8) | 14.4 (4.2, 27.5) | 6.6 (−2.7, 18.6) | 0.049 |
| ΔSDNN (ms) | 1.7 (−5.9, 13.9) | 6.7 (−6.9, 23.7) | 4.7 (−7.1, 18.6) | 0.499 |
| ΔLF (ms2) | −612.5 (−827.2, −93.3) | −26.1 (−433.4, 249.3) ^ | 22.2 (−118.2, 181.9) ^ | 0.001 |
| ΔHF (ms2) | 130.5 (36.7, 311.5) | 152 (58.6, 406.1) | 48.0 (−14.0, 90.0) ^° | 0.003 |
| ΔLF/HF | −5.8 ± 4.9 | −3.0 (−6.6, −1) ^ | −0.7 (−3.7, 0.5) ^° | 0.001 |
| ΔHFn (n.u.) | 30 ± 19.3 | 19.6 ± 17.1 | 5.3 (−2.3, 14) ^° | <0.001 |
| ΔLFn (n.u.) | −30.2 ± 19.3 | −19.5 ± 17.1^ | −5.1 (−14, 2.3) ^° | <0.001 |
| Δα1 | −0.4 ± 0.2 | −0.3 ± 0.3 | −0.1 ± 0.3 ^° | <0.001 |
| ΔSampEn | 0.3 ± 0.5 | 0.3 ± 0.4 | 0.1 ± 0.4 | 0.139 |
^ Comparing with NAV (p < 0.017); ° Comparing with AVSc (p < 0.017). p: adjusted value of p according to the Bonferroni correction for multiple comparisons. NAV: normal aortic valve; AVSc: aortic valve sclerosis; AVSt: aortic valve stenosis. Δ: difference between values obtained at the supine position minus values at active standing. meanNN: mean value of all NN intervals (RR intervals from sinus rhythm), SDNN: standard deviation of all NN intervals; RMSSD: root mean squared of the successive differences; pNN20: percentage of successive NN intervals with differences greater than 20 ms; LF: low-frequency band spectral power; HF: high-frequency band spectral power; HFn: HF in normalized units; LFn: LF in normalized units; LF/HF: ratio between low-frequency and high frequency band indices; α1: short-term scaling exponent; SampEn: sample entropy.
Results of the hierarchical partitioning analysis for each independent variable (indicated as HRV in the first column). The name of the independent variables and its independent contribution to the R² of the hierarchical partitioning combined final analysis are shown in columns 2 and 3. The models where there were no valve parameter function-independent variables included are indicated as dashed lines (----). The column 4 shows the pre-selected covariables included in the hierarchical partitioning analysis, as previously selected by applying multiple linear stepwise regression models for each dependent variable (see Section 2.8). The last column provides the R2 of the combined model assessed by the hierarchical partitioning analysis.
| HRV | Valve Function Parameter (Independent Variable) | Pre-Selected Covariables | R2 of Combined Model | |
|---|---|---|---|---|
| Name | % Independent Exploratory Capacity | |||
| ΔpNN20 | PGmean | 3.951 | age, albumin, CRP, medication intake, ΔmeanNN | 0.2890 |
| ΔmeanNN | PGmean | 2.519 | LVMi, glucose, tri | 0.2525 |
| ΔRMSSD | ---- | ---- | age, medication intake, ΔmeanNN | 0.2966 |
| ΔSDNN | ---- | ---- | CRP, IFN-γ, BMI, medication intake | 0.2102 |
| ΔLF | ---- | ---- | RWT, CRP, TIMP1, BMI | 0.2439 |
| ΔHF | PGmean | 1.698 | SBP, ΔmeanNN | 0.2244 |
| ΔLF/HF | PGmax | 1.109 | PGmax, RWT, SBP, medication intake, MBF, ΔmeanNN | 0.1643 |
| ΔHFn | PGmean | 2.432 | LVM, glucose, triglycerides, ET1, SBP, DBP, MBF, ΔmeanNN | 0.3077 |
| ΔLFn | PGmean | 2.390 | LVM, glucose, triglycerides, ET1, SBP, DBP, MBF, ΔmeanNN | 0.3005 |
| Δα1 | AVA | 4.591 | RWT, LVEF, triglycerides, ET1, IL-4, SBP, age, medication intake, MBF, ΔmeanNN | 0.2960 |
| ΔSampEn | PGmean | 0.985 | MMP2/TIMP1, SBP, ΔmeanNN | 0.1717 |
Δ: difference between values obtained at the supine position minus values at active standing; MeanNN: mean value of all NN intervals (RR intervals from sinus rhythm), SDNN: standard deviation of all NN intervals; RMSSD: root mean squared of the successive differences; pNN20: percentage of successive NN intervals with differences greater than 20 ms; LF: low-frequency band spectral power; HF: high-frequency band spectral power; HFn: HF in normalized units; LFn: LF in normalized units; LF/HF: ratio between low-frequency and high frequency band indices; α1: short-term scaling exponent; SampEn: sample entropy; LVEF: left ventricular ejection fraction; LVM: left ventricular mass; LVMi: left ventricular mass indexed to body surface area; RWT: relative wall thickness. Vmax: maximum aortic valve transvalvular velocity; PGmean: mean pressure gradient; PGmax: maximum pressure gradient; AVA: aortic valve area; BMI: body mass index; SBP: systolic blood pressure; DBP: diastolic blood pressure; MBF: mean breathing frequency; IL-4: interleukin 4; IFN-γ: interferon gamma; MMP2: matrix metalloproteinase 2; TIMP1: tissue inhibitors of metalloproteinases 1; ET1: endothelin 1; CRP: C-reactive protein.